Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24833
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMano, Roy-
dc.contributor.authorDuzgol, Cihan-
dc.contributor.authorGanat, Maz-
dc.contributor.authorGoldman, Debra A-
dc.contributor.authorBlum, Kyle A-
dc.contributor.authorSilagy, Andrew W-
dc.contributor.authorWalasek, Aleksandra-
dc.contributor.authorSanchez, Alejandro-
dc.contributor.authorDiNatale, Renzo G-
dc.contributor.authorMarcon, Julian-
dc.contributor.authorKashan, Mahyar-
dc.contributor.authorBecerra, Maria F-
dc.contributor.authorBenfante, Nicole-
dc.contributor.authorColeman, Jonathan A-
dc.contributor.authorKattan, Michael W-
dc.contributor.authorRusso, Paul-
dc.contributor.authorAkin, Oguz-
dc.contributor.authorOstrovnaya, Irina-
dc.contributor.authorHakimi, A Ari-
dc.date2020-09-06-
dc.date.accessioned2020-09-28T23:22:11Z-
dc.date.available2020-09-28T23:22:11Z-
dc.date.issued2020-11-
dc.identifier.citationUrologic Oncology 2020; 38(11): 853.e1-853.e7en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/24833-
dc.description.abstractPreoperative models, based on patient and tumor characteristics, predict risk for adverse outcomes after nephrectomy. Changes in renal tumor characteristics over the last decades, warrant further evaluation using contemporary cohorts. We aimed to validate a previously published preoperative nomogram predicting 12-year metastasis-free probability after nephrectomy for localized renal tumors in a contemporary cohort. After obtaining institutional review board approval, data of 1,760 patients who underwent nephrectomy for a localized renal mass between 2005 and 2011 were reviewed. Preoperative images were evaluated for the presence of tumor necrosis, lymphadenopathy, and tumor size. The study outcome was metastatic-free probability. Model discrimination was assessed with Gönen and Heller's concordance probability estimate, and calibration was evaluated. The cohort included 1,102 male and 658 female patients with a median age of 60 years. Most patients presented incidentally (84%). On imaging, 3% had evidence of lymphadenopathy, 55% had necrosis and median tumor diameter was 3.7 cm (interquartile range [IQR]: 2.5, 5.5). Median follow-up in non-metastatic patients was 7.7 years (IQR: 5.3, 9.7). Estimated 12-year metastatic-free probability was 88% (86%-90%). The model showed strong discrimination (concordance probability estimate [CPE]: 0.77), and fair calibration. The time-dependent receiver operating characteristic (ROC) curves showed strong discrimination at all-time points and the area under the curve (AUC) for year 12 was 0.83 (95% Confidence Interval: 0.78-0.89). We validated the preoperative nomogram of 12-year metastasis-free probability in a contemporary cohort despite different tumor characteristics. Future studies should evaluate the role of preoperative risk stratification in patient selection for neoadjuvant treatment.en
dc.language.isoeng
dc.subjectMetastasesen
dc.subjectNephrectomyen
dc.subjectNomogramen
dc.subjectOutcomeen
dc.subjectPreoperativeen
dc.subjectRenal cell carcinomaen
dc.titlePreoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort.en
dc.typeJournal Articleen
dc.identifier.journaltitleUrologic Oncologyen
dc.identifier.affiliationDepartment of Urology, Miller School of Medicine, University of Miami, Miami, FLen
dc.identifier.affiliationDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationDepartment of Urology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israelen
dc.identifier.affiliationDepartment of Urology, Ludwig-Maximilians-Universität München, Munich, Germanyen
dc.identifier.affiliationDepartment of Urology, SUNY Downstate Medical Center, Brooklyn, NYen
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Surgery, Division of Urologic Oncology, Englewood Health, Englewood, NJen
dc.identifier.affiliationDepartment of Urology, University of Texas Health Science Center at Houston, Houston, TXen
dc.identifier.affiliationDivision of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UTen
dc.identifier.affiliationDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.affiliationDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OHen
dc.identifier.affiliationDepartment of Surgery, Division of Urologic Oncology, Englewood Health, Englewood, NJen
dc.identifier.affiliationUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.en
dc.identifier.doi10.1016/j.urolonc.2020.07.019en
dc.type.contentTexten
dc.identifier.pubmedid32900625
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Oct 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.